Stocks and Investing Stocks and Investing
Thu, July 22, 2021
Wed, July 21, 2021

Tazeen Ahmad Maintained (ACAD) at Hold with Increased Target to $26 on, Jul 21st, 2021


Published on 2024-10-27 17:16:30 - WOPRAI, Tazeen Ahmad
  Print publication without navigation


Tazeen Ahmad of B of A Securities, Maintained "ACADIA Pharmaceuticals Inc." (ACAD) at Hold with Increased Target from $24 to $26 on, Jul 21st, 2021.

Tazeen has made no other calls on ACAD in the last 4 months.



There are 8 other peers that have a rating on ACAD. Out of the 8 peers that are also analyzing ACAD, 6 agree with Tazeen's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Esther Hong of "Berenberg" Initiated at Hold and Held Target at $29 on, Thursday, June 10th, 2021
  • Sumant Kulkarni of "Canaccord Genuity" Maintained at Hold with Increased Target to $27 on, Wednesday, May 12th, 2021
  • Andrew Fein of "HC Wainwright & Co." Downgraded from Strong Buy to Hold and Decreased Target to $18 on, Wednesday, April 7th, 2021
  • Chris Howerton of "Jefferies" Downgraded from Strong Buy to Hold and Decreased Target to $21 on, Tuesday, April 6th, 2021
  • Vamil Divan of "Mizuho" Downgraded from Strong Buy to Hold and Held Target at $25 on, Tuesday, April 6th, 2021
  • Salveen Richter of "Goldman Sachs" Downgraded from Strong Buy to Hold and Decreased Target to $25 on, Tuesday, April 6th, 2021


These are the ratings of the 2 analyists that currently disagree with Tazeen


  • Jeffrey Hung of "Morgan Stanley" Maintained at Buy with Increased Target to $29 on, Thursday, May 6th, 2021
  • Joseph Stringer of "Needham" Maintained at Strong Buy with Decreased Target to $30 on, Monday, April 5th, 2021
Contributing Sources